APA (7th ed.) Citation

A, O., S, S., N, N., M, N., M, C., AM, R., . . . G, N. (2019). Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: The CIFRA study protocol. BMC cancer, 19(1), 899. https://doi.org/10.1186/s12885-019-6109-z

Chicago Style (17th ed.) Citation

A, Ottaiano, et al. "Cetuximab, Irinotecan and Fluorouracile in FiRst-line Treatment of Immunologically-selected Advanced Colorectal Cancer Patients: The CIFRA Study Protocol." BMC Cancer 19, no. 1 (2019): 899. https://doi.org/10.1186/s12885-019-6109-z.

MLA (9th ed.) Citation

A, Ottaiano, et al. "Cetuximab, Irinotecan and Fluorouracile in FiRst-line Treatment of Immunologically-selected Advanced Colorectal Cancer Patients: The CIFRA Study Protocol." BMC Cancer, vol. 19, no. 1, 2019, p. 899, https://doi.org/10.1186/s12885-019-6109-z.